Nexus Surgical & Medicare Limited has submitted its quarterly compliance certificate to BSE Limited as required under SEBI regulations. The submission, dated 8th April, 2026, fulfills the company's regulatory obligations for the quarter ended 31st March, 2026.

Regulatory Compliance Submission

The company submitted its Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for Q4 FY26. The certificate was prepared and issued by M/s. Purva Sharegistry (India) Private Limited, which serves as the Registrar and Share Transfer Agent (RTA) for Nexus Surgical And Medicare Limited.

Certificate Details and Confirmation

Purva Sharegistry confirmed compliance with all regulatory requirements regarding dematerialisation processes during the quarter. The RTA certified that any securities received from depository participants for dematerialisation were properly confirmed to the depositories within prescribed timelines.

Dematerialisation Activity

The detailed report accompanying the certificate shows no dematerialisation activity during the quarter ended 31st March, 2026. All entries in the dematerialisation register, including folio numbers, shareholder names, certificate numbers, and share quantities, were marked as 'NIL', indicating no share certificates were processed for dematerialisation during this period.

Corporate Governance

The submission was signed by Monika Choudhary, Company Secretary (Membership No. F12660), demonstrating the company's commitment to maintaining proper corporate governance standards. The timely submission of this certificate ensures compliance with SEBI's regulatory framework for depositories and participants, maintaining transparency in the company's share transfer and dematerialisation processes.

Nexus Surgical & Medicare Limited has delivered impressive financial performance for the third quarter of FY26, with the Board of Directors approving unaudited results that showcase strong growth across revenue and profitability metrics. The company's results were approved during a board meeting held on February 14, 2026, at the company's registered office in Vasai, Maharashtra.

Quarterly Financial Performance

The company demonstrated exceptional quarterly performance with significant improvements in both revenue and profitability metrics compared to the previous year.

The company's sales revenue surged to ₹293.08 lakhs in Q3 FY26, nearly doubling from ₹148.39 lakhs in the corresponding quarter of the previous year. This remarkable 97.55% growth in sales was accompanied by strong operational efficiency, resulting in net profit growth of 49.76% to ₹17.01 lakhs.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Nexus Surgical and Medicare Limited maintained its growth trajectory with consistent improvements across key financial parameters.

The nine-month results reflect sustained business momentum, with sales growing 37.34% to ₹582.19 lakhs and net profit increasing 21.29% to ₹49.62 lakhs compared to the same period in the previous year.

Operational Metrics and Expenses

The company's expense management showed mixed trends during the quarter. Total expenses for Q3 FY26 stood at ₹270.38 lakhs compared to ₹133.21 lakhs in Q3 FY25. Key expense components included:

• Purchase of stock-in-trade: ₹97.63 lakhs (Q3 FY26) vs ₹63.30 lakhs (Q3 FY25)
• Other expenses: ₹204.16 lakhs (Q3 FY26) vs ₹98.83 lakhs (Q3 FY25)
• Employee benefits expense: ₹0.62 lakhs (Q3 FY26) vs ₹4.87 lakhs (Q3 FY25)

The company benefited from a positive change in inventories of stock-in-trade worth ₹32.13 lakhs during Q3 FY26, compared to a negative change of ₹33.89 lakhs in the corresponding quarter last year.

Earnings Per Share and Capital Structure

Basic and diluted earnings per share for Q3 FY26 stood at ₹0.31, representing an improvement from ₹0.21 in Q3 FY25. For the nine-month period, earnings per share increased to ₹0.91 from ₹0.75 in the previous year. The company's paid-up equity share capital remained stable at ₹547.19 lakhs, consisting of equity shares of ₹10 each.

Corporate Governance and Compliance

The financial results were reviewed and recommended by the audit committee before board approval. The company's statutory auditors, Satya Prakash Natani & Co., conducted a limited review of the results. The company reported no shareholder or investor complaints during the quarter ended December 31, 2025, reflecting strong corporate governance practices.